Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Stagg

Showing results (21-30 of 108) with videos related to

Pageof 11
Sort By:
Science Immunology|July 7, 2023
The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapyJohn Stagg, Encouse Golden, Erik Wennerberg, et al.
Nature Reviews. Clinical Oncology|June 10, 2020
The adenosine pathway in immuno-oncologyBertrand Allard, David Allard, Laurence Buisseret, et al.
Immunological Reviews|November 6, 2007
From cancer immunosurveillance to cancer immunotherapyJohn Stagg, Ricky W Johnstone, Mark J Smyth
Journal of Biomedicine & Biotechnology|November 6, 2012
Ectonucleotidases in cancer and inflammationJohn Stagg, Linda F Thompson, Karen M Dwyer
Methods in Molecular Biology (Clifton, N.J.)|December 31, 2022
Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor ModelsCelia Jacoberger-Foissac, Bertrand Allard, David Allard, et al.
Cancer Discovery|July 19, 2014
Targeting cancer-derived adenosine: new therapeutic approachesArabella Young, Deepak Mittal, John Stagg, et al.
Cancer Research|December 18, 2004
Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapyJohn Stagg, Jian Hui Wu, Nathaniel Bouganim, et al.
Oncoimmunology|July 29, 2016
CD73-adenosine reduces immune responses and survival in ovarian cancer patientsPierre-Olivier Gaudreau, Bertrand Allard, Martin Turcotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2013
Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbsBertrand Allard, Sandra Pommey, Mark J Smyth, et al.
Biomarkers in Cancer|May 12, 2016
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsPierre-Olivier Gaudreau, John Stagg, Denis Soulières, et al.
Pageof 11

Showing results (21-30 of 108) with videos related to

Sort By:
Pageof 11
Science Immunology|July 7, 2023
The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapyJohn Stagg, Encouse Golden, Erik Wennerberg, et al.
Nature Reviews. Clinical Oncology|June 10, 2020
The adenosine pathway in immuno-oncologyBertrand Allard, David Allard, Laurence Buisseret, et al.
Immunological Reviews|November 6, 2007
From cancer immunosurveillance to cancer immunotherapyJohn Stagg, Ricky W Johnstone, Mark J Smyth
Journal of Biomedicine & Biotechnology|November 6, 2012
Ectonucleotidases in cancer and inflammationJohn Stagg, Linda F Thompson, Karen M Dwyer
Methods in Molecular Biology (Clifton, N.J.)|December 31, 2022
Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor ModelsCelia Jacoberger-Foissac, Bertrand Allard, David Allard, et al.
Cancer Discovery|July 19, 2014
Targeting cancer-derived adenosine: new therapeutic approachesArabella Young, Deepak Mittal, John Stagg, et al.
Cancer Research|December 18, 2004
Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapyJohn Stagg, Jian Hui Wu, Nathaniel Bouganim, et al.
Oncoimmunology|July 29, 2016
CD73-adenosine reduces immune responses and survival in ovarian cancer patientsPierre-Olivier Gaudreau, Bertrand Allard, Martin Turcotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2013
Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbsBertrand Allard, Sandra Pommey, Mark J Smyth, et al.
Biomarkers in Cancer|May 12, 2016
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsPierre-Olivier Gaudreau, John Stagg, Denis Soulières, et al.
Pageof 11